

# Myositis

CHI Formulary Treatment algorithm

Treatment algorithm- December  
2023

Supporting treatment algorithms  
for the clinical management of  
Myositis

Figures 1 and 2 outline a comprehensive treatment algorithm on **the management of Myositis** aimed at addressing the different lines of treatment after thorough review of medical and economic evidence by CHI committees.

For further evidence, please refer to CHI **Myositis** full report. You can stay updated on the upcoming changes to our formulary by visiting our website at <https://chi.gov.sa/AboutCCHI/CCHIprograms/Pages/IDF.aspx>

Our treatment algorithm offers a robust framework for enhancing patient care and optimizing treatment outcomes across a range of treatment options, holding great promise for improving healthcare delivery.

First-line therapy:	Glucocorticoids	and	Methotrexate or azathioprine	and/or	IVIG
Second-line therapy:	Glucocorticoids	and	MMF, tacrolimus or ciclosporin or combination therapy of methotrexate and azathioprine	and/or	IVIG
Third-line therapy:	Glucocorticoids	and	Rituximab, cyclophosphamide, RCI or other biologic agents	and/or	IVIG

Figure 1: Overview of pharmacological therapy in idiopathic inflammatory myopathies

1

<sup>1</sup> Retrieved from Oddis C V., Aggarwal R. Treatment in myositis. Nat Rev Rheumatol. 2018;14(5):279-289. doi:10.1038/nrrheum.2018.42




Figure 2: Proposed approach to treating myositis-associated interstitial lung cancer

<sup>2</sup> Retrieved from Oddis C V., Aggarwal R. Treatment in myositis. Nat Rev Rheumatol. 2018;14(5):279-289. doi:10.1038/nrrheum.2018.42